p. 154−155
2345-3656
Vol.15/No.3
p. 156−160
2345-3656
Vol.15/No.3
p. 161−166
2345-3656
Vol.15/No.3
p. 167−174
2345-3656
Vol.15/No.3
140 ± /l (100%). Conclusion: Younger age, lower WBC count and higher platelet count were significantly associated with longer survival in AML patients with t(15;17)(q22; q12).]]>
p. 175−181
2345-3656
Vol.15/No.3
p. 182−188
2345-3656
Vol.15/No.3
p. 189−196
2345-3656
Vol.15/No.3
p. 197−204
2345-3656
Vol.15/No.3
p. 205−216
2345-3656
Vol.15/No.3
p. 217−224
2345-3656
Vol.15/No.3
p. 225−231
2345-3656
Vol.15/No.3
p. 232−238
2345-3656
Vol.15/No.3
75% (4). The aggregation of these two scores was used as the final score ranging from 0 to 7. While 4-7 scores were selected as positive, the others were included in the AR-negative expression group. Fisher's exact test was used to analyze the AR expression correlation with the clinicopathological parameters. Result : Positive immunoreactivity for AR was observed in 8 out of 76 (11%) specimens. No-correlation (P>0.05) was observed between the AR expression and grade, stage, lymph node status, and Ki-67 level. The AR-positive patients exhibited older age at the time of diagnosis (P=0.0339) and larger tumor size (P=0.0224) in comparison with the AR-negative patients. Low percentage of TNBC patients expressed AR and no significant correlation was observed between its expression and most of the clinicopathological parameters. Conclusion : AR may not be a suitable biomarker and treatment target for the Iranian patients with TNBC.]]>
p. 239−244
2345-3656
Vol.15/No.3
p. 245−250
2345-3656
Vol.15/No.3
p. 251−255
2345-3656
Vol.15/No.3
p. 256−258
2345-3656
Vol.15/No.3